Bibliografie alfabetic

1. Ambrsio A. F., Soares-da-Silva P., Carvalho C. M., Carvalho A. P., Mechanisms of

Action of Carbamazepine and Its Derivatives, Oxcarbazepine, BIA 2-093, and BIA 2-024,
Neurochemical Research, Vol. 27, Nos. 1/2, Feb. 2002, pp. 12130
2. Bllu D., Baconi D., Toxicologia substanelor medicamentoase de sintez, Ed.
Tehnoplast, Bucureti, 2005; 29-30, 152-59.
3. Benjamin S. M. (Editor), Focus on Epilepsy Research, Nova Biomedical Books, New
York, 2004; 202-10
4. Berg AT, Shinnar S. The risk of seizure recurrence following a first unprovoked
seizure: a quantitative review. Neurology 1991; 41: 96572.
5. Brewerton T. D., Jackson C.W., "Prophylaxis of carbamazepine-induced hyponatremia
by demeclocycline in 6 patients." J Clin Psychiatry 55 (1994): 249-51
6. Clark B.J., Frost T., Russel M. A. (editor), UV Spectroscopy Techniques,
instrumentation, data handling, Chapman and Hall, 1993; 1-2
7. Cristea A. N.(sub redacia), Tratat de farmacologie, Editura Medical, Bucureti,
2005; 128-31
8. Delzompo M, Bocchetta A, Loviselli A, Martino E, Post RM, Ketter TA "Thyroid
function during carbamazepine." Biol Psychiatry 36 (1994): 135-6
9. Engel J., Jr., A Proposed Diagnostic Scheme for People with Epileptic Seizures and
with Epilepsy: Report of the ILAE Task Force on Classification and Terminology,
Epilepsia, Vol. 42, 2001: 796-803
10. Fisher, R. S., Cross, J. H., French, J. A., Higurashi, N., Hirsch, E., Jansen, F. E.,
Lagae, L., Mosh, S. L., Peltola, J., Roulet Perez, E., Scheffer, I. E. and Zuberi, S. M.
(2017), Operational classification of seizure types by the International League Against
Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.
Epilepsia, Vol 58: 52230
11. Gidal B. E, Zupanc M. L., Potential pharmacokinetic interaction between felbamate
and phenobarbital, Annals of Pharmacotherapy, Apr., 1994;
12. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes, and consequences. New
York: Demos Publications; 1990.
13. Hesdorffer D. C., Berg A.T, Kanner A. M,, An Update on Antiepileptic Drugs and
Suicide: Are There Definitive Answers Yet?, Epilepsy Currents, Nov, 2010; 137-45
14. Hussein A., Abdulgalil A., Omer F., Eltoum H., Hamad A., El-Adil O., Mubarak B.,
Malkaldar M., Idris I., Alwidaa Y., Mahmoud E., Correlation between Serum Level of
Antiepileptic Drugs and their Side Effects, Oman Medical Journal, 2010, Jan; 25(1); 17-
21
15. ILAE, Proposal for Revised Clinical and Electroencephalographic Classification of
Epileptic Seizures, Epilesia, Vol. 22, 1981: 489501.
16. Jallon P., Use of mefloquine in epileptic patients, Journal of Nerurology,
Neurosurgery and Psychiatry, 1988; May; 51(5): 732
17. Jasper H.H., Noebels J. L., M. Avoli, M. A. Rogawski, R.W. Olsen, A. V. Delgado -
Escueta Jaspers Basic Mechanisms of the Epilepsies, Fourth Edition, 2012; 4-5
18. Jerome Engel, Jr, ILAE Classification of epilepsy syndromes, Epilepsy Research,
Elsevier, 70S, 2006; S5-S10.
19. Kalff R, Houtkooper MA, Meyer JW, et al "Carbamazepine and serum sodium levels."
Epilepsia 24 (1984): 390-7
20. Kuz G.M, Manssourian A., "Carbamazepine-induced hyponatremia: assessment of risk
factors." Ann Pharmacother 39 (2005): 1943-6
21. Lofgren E, Tapanainen JS, Koivunen R, Pakarinen A, Isojarvi JI "Effects of
carbamazepine and oxcarbazepine on the reproductive endocrine function in women with
epilepsy." Epilepsia 47 (2006): 1441-6
22. Macdonald R. L., Kelly K. M., Antiepileptic Drug Mechanisms of Action, Epilepsia,
Vol. 34, Suppl. 5, 1993
23. Mori H, Takahashi K, Mizutani T, Interaction between valproic acid and carbapenem
antibiotics, Drug Metabolite Reviews, 2007;39(4):647-57.
24. Nica S., erbnescu A., Davidescu I., Epilepsia Reflex, Revista Romn de
Neurologie, Nr 1, 2006; 23-26
25. Noh Y, Kim DW, Chu K, Lee ST, Jung KH, Moon HJ, Lee SK, Topiramate increases
the risk of valproic acid-induced encephalopathy, Epilepsia, 2013, Jan; 54 (1)
26. Panayiotopoulos C.P., A Clinical Guide to Epileptic Syndromes and their Treatment,
Second edition, 2010;
27. Panea C., Bjenaru O., erbnescu A., Epilepsia Adultului Ghid de diagnostic i
tratament, 27-31, 8-9, 39-52, Anexa 11
28. Parke-Davis, Division of Pfizer Inc. Phenytoin sodium capsules, extended release
prescribing information. New York, NY; 2011 Aug.
29. Perkampus H.H., UV-VIS Spectroscopy and its Applications, Springer-Verlag Berlin
Heidelberg, 1992; 2-10
30. Popescu F. D., Udritoiu I., Popescu F., Vieru M., Sindromul de hipersensibilitate la
anticonvulsivante, Jurnalul Naional de Psihofarmacologie, Vol. 5, Nr 1,2, 2005;
31. Popescu V., Etiologia Convulsiilor Neonatale, Practica Medical, Vol.1, Nr. 3-4,
2006; 104-9
32. Rudolf G., Valenti M.P., Hirsch E. Genetic reflex epilepsies. Orphanet Encyclopedia,
2004
33. Serma J., Fried B.(editor), Handbook of Thin Layer Cromatography, Third Edition,
Revised and Expanded, Marel Dekker, Inc. 2003; 1-29
34. Simon Shorvon, Epilepsy, Oxford Universily Press, 2009; 1
35. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F "Thyroid hormones in
epileptic children receiving carbamazepine and valproic acid." Pediatr Neurol 25 (2001):
43-6
36. Wu J.B., Valproic acid induces monoamine oxidase A via Akt/forkhead box O1
activation, Molecular Pharmacology, Oct., 2011;
37. ***Diaconu G., Convlusiile i epilepsiile,
http://www.umfiasi.ro/Rezidenti/suporturidecurs/Facultatea%20de%20Medicina/Conf.dr.
Diaconu%20Georgeta%20curs%20rezidenti/curs%20rezidenti%20-
%20CONVULSIILE%20si%20EPILEPSIILE.doc
38. ***Novartis Pharmaceuticals Corporation. Tegretol (carbamazepine) chewable tablets,
tablets, and suspension and Tegretol-XR (carbamazepine) extended-release tablets
prescribing information. East Hanover, NJ; 2009 https://www.drugs.com/sfx/tegretol-side-
effects.html
39. ***Sanofi-Aventis, Depakine Chrono, 500 mg, AUTORIZAIE DE PUNERE PE
PIA NR. 1671/2009/01, Anexa 2 http://www.anm.ro/_/_RCP/rcp_1671_25.05.09.pdf